Evidence map›Paper›PMID 40100465›Full record

ReviewMedical oncology (Northwood, London, England)2025

Exosomes derived from natural killer cells: transforming immunotherapy for aggressive breast cancer.

Abdulmalik Saleh Alfawaz Altamimi, M Arockia Babu, Muhammad Afzal, Ashok Kumar Bishoyi, R Roopashree, Suman Saini, R S K Sharma, Piyus Kumar Pathak, Ashish Singh Chauhan, Kavita Goyal and 3 more

Abstract readReview
PubMed Publisher
In one paragraph

Review in Medical oncology (Northwood, London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Abdulmalik Saleh Alfawaz AltamimiDepartment of Pharmaceutical Chemistry, College of Pharmacy, Prince Sattam Bin Abdulaziz University, 11942, Al Kharj, Saudi Arabia.
M Arockia BabuInstitute of Pharmaceutical Research, GLA University, Mathura, Uttar Pradesh, India.
Muhammad AfzalDepartment of Pharmaceutical Sciences, Pharmacy Program, Batterjee Medical College, P.O. Box 6231, 21442, Jeddah, Saudi Arabia.
Ashok Kumar BishoyiDepartment of Microbiology, Faculty of Science, Marwadi University Research Center, Marwadi University, Rajkot, Gujarat, 360003, India.
R RoopashreeDepartment of Chemistry and Biochemistry, School of Sciences, JAIN (Deemed to be University), Bangalore, Karnataka, India.
Suman SainiDepartment of Chemistry, Chandigarh Engineering College, Chandigarh Group of Colleges-Jhanjeri, Mohali, Punjab, 140307, India.
R S K SharmaDepartment of Chemistry, Raghu Engineering College, Visakhapatnam, Andhra Pradesh, 531162, India.
Piyus Kumar PathakDepartment of Applied Sciences-Chemistry, NIMS Institute of Engineering & Technology, NIMS University Rajasthan, Jaipur, India.
Ashish Singh ChauhanDivision of Research and Innovation, Uttaranchal Institute of Pharmaceutical Sciences, Uttaranchal University, Dehradun, Uttarakhand, India.
Kavita GoyalDepartment of Biotechnology, Graphic Era (Deemed to be University), Clement Town, Dehradun, 248002, India.
Haider AliFaculty of Medicine, Ala-Too International University, Bishkek, Kyrgyz Republic.
Nawaid Hussain KhanFaculty of Medicine, Ala-Too International University, Bishkek, Kyrgyz Republic.
Ashok Kumar BalaramanResearch and Enterprise, University of Cyberjaya, Persiaran Bestari, Cyber 11, 63000, Cyberjaya, Selangor, Malaysia. ashok.cyberjaya@outlook.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Natural killer cell-derived exosomes (NK-Exos) hold great promise as immune modulators and immunotherapeutics against cancer due to their intrinsically latent anti-tumor effects. They use these nanosized vesicles to deliver cytotoxic molecules, such as perforin, granzymes, and miRNAs, directly to cancer cells to kill them, avoiding immune suppression. NK-Exos has particular efficacy for treating aggressive breast cancer by modulating the TME to activate the immune response and suppress immunosuppressive factors. Bioengineering advances have extended the therapeutic potential of NK-Exos, which permits precise tumor cell targeting and efficient delivery of therapeutic payloads, including small RNAs and chemotherapeutic agents. In engineered NK-Exos, sensitization of cancer cells to apoptosis, reduction of tumor growth, and resistance to drugs have been demonstrated to be highly effective. When combined, NK-Exos synergizes with radiotherapy, chemotherapy, or checkpoint inhibitors, enhancing therapeutic efficacy, and minimizing systemic toxicity. This review emphasizes the critical role of NK-Exos in breast cancer treatment, their integration into combination therapies, and the need for further research to overcome existing limitations and fully realize their clinical potential.

Indexed as

Breast NeoplasmsExosomesImmunotherapyKiller Cells, NaturalAnimalsFemaleHumansBreast cancerCancer immunotherapyExosomesExtracellular vesiclesNatural killer cells

Identifiers

PMID40100465

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.